Ignite Creation Date:
2025-12-25 @ 4:56 AM
Ignite Modification Date:
2026-03-02 @ 8:38 AM
Study NCT ID:
NCT03049618
Status:
COMPLETED
Last Update Posted:
2025-10-22
First Post:
2017-02-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
Sponsor:
University of Southern California
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | ALK Gene Mutation | View |
| None | BRAF Gene Mutation | View |
| None | EGFR Gene Mutation | View |
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | Metastatic Head and Neck Carcinoma | View |
| None | Recurrent Head and Neck Carcinoma | View |
| None | Recurrent Non-Small Cell Lung Carcinoma | View |
| None | ROS1 Gene Mutation | View |
| None | Stage III Non-Small Cell Lung Cancer | View |
| None | Stage IIIA Non-Small Cell Lung Cancer | View |
| None | Stage IIIB Non-Small Cell Lung Cancer | View |
| None | Stage IV Non-Small Cell Lung Cancer | View |
Keywords: